Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer

Cell Cycle

Volumn 9, Issue 9, 2010, Pages 1738-1741

  Hohla, Florian ^a,b,c   Schally, Andrew V ^b,c  

^a UNIVERSITY OF SALZBURG   (Austria)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bombesin gastrin releasing peptide analogs; Bombesin gastrin releasing peptide receptors; Cytotoxic analogs; Targeted therapy

Indexed keywords

BOMBESIN; BOMBESIN RECEPTOR; GASTRIN ANTAGONIST; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; HG 6 VACCINE; MONOCLONAL ANTIBODY; NEUROMEDIN B; PD 176252; RC 3095; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTISENSE THERAPY; BREAST TUMOR; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL KILLING; CELL PROLIFERATION; CLINICAL TRIAL; CYTOTOXICITY; HUMAN; IMMUNOREACTIVITY; INTRACELLULAR SIGNALING; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MUSCLE EXCITATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; REVIEW; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

MAMMALIA;

EID: 77953555625     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.9.11347     Document Type: Review

References (76)

1. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling and functions in normal and disease states. Pharmacol Rev 2008; 60:1-42.
2. Schally AV. Hypothalamic hormones: from neuroendocrinology to cancer therapy. Anticancer Drugs 1994; 5:115-30.
3. Spindel ER, Giladi E, Segerson TP, Nagalla S. Bombesin-like peptides: of ligands and receptors. Recent Prog Horm Res 1993; 48:365-91.
4. Sunday ME, Kaplan LM, Motoyama E, Chin WW, Spindel ER. Gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease. Lab Invest 1988; 59:5-24.
5. Erspamer V, Erspamer GF, Inselvini M, Negri L. Occurrence of bombesin and alytesin in extracts of the skin of three European discoglossid frogs and pharmacological actions of bombesin on extravascular smooth muscle. Br J Pharmacol 1972; 45:333-48.
6. Erspamer V, Erpamer GF, Inselvini M. Some pharmacological actions of alytesin and bombesin. J Pharm Pharmacol 1970; 22:875-6.
7. McDonald TJ, Jornvall H, Nilsson G, Vagne M, Ghatei M, Bloom SR, et al. Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. Biochem Biophys Res Commun 1979; 90:227-33. (Pubitemid 10242631)
8. Minamino N, Kangawa K, Matsuo H. Neuromedin B: a novel bombesin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun 1983; 114:541-8.
9. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res 1994; 54:5895-901. (Pubitemid 24375225)
10. Kim S, Hu W, Kelly DR, Hellmich MR, Evers BM, Chung DH. Gastrin-releasing peptide is a growth factor for human neuroblastomas. Ann Surg 2002; 235:621-9.
11. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985; 316:823-6. (Pubitemid 15003742)
12. Jensen JA, Carroll RE, Benya RV. The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 2001; 22:689-99.
13. Glover SC, Tretiakova MS, Carroll RE, Benya RV. Increased frequency of gastrin-releasing peptide receptor gene mutations during colon-adenocarcinoma progression. Mol Carcinog 2003; 37:5-15.
14. Gorbulev V, Akhundova A, Buchner H, Fahrenholz F. Molecular cloning of a new bombesin receptor subtype expressed in uterus during pregnancy. Eur J Biochem 1992; 208:405-10.
15. 4). Proc Natl Acad Sci USA 1995; 92:6205-9.
16. Currie S, Smith GL, Crichton CA, Jackson CG, Hallam C, Wakelam MJ. Bombesin stimulates the rapid activation of phospholipase A2-catalyzed phosphatidylcholine hydrolysis in Swiss 3T3 cells. J Biol Chem 1992; 267:6056-62.
17. MacKinnon AC, Waters C, Jodrell D, Haslett C, Sethi T. Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism. J Biol Chem 2001; 276:28083-91.
18. Cook SJ, Briscoe CP, Wakelam MJ. The regulation of phospholipase D activity and its role in sn-1,2-diradylglycerol formation in bombesin- and phorbol 12-myristate 13-acetate-stimulated Swiss 3T3 cells. Biochem J 1991; 280:431-8.
19. Rozengurt E, Sinnett-Smith J. Bombesin stimulation of DNA synthesis and cell division in cultures of Swiss 3T3 cells. Proc Natl Acad Sci USA 1983; 80:2936-40. (Pubitemid 13104152)
20. Rozengurt E, Murray M, Zachary I, Collins M. Protein kinase C activation enhances cAMP accumulation in Swiss 3T3 cells: inhibition by pertussis toxin. Proc Natl Acad Sci USA 1987; 84:2282-6. (Pubitemid 17075855)
21. Rozengurt EV. Gastrointestinal peptide signaling through tyrosine phosphorylation of focal adhesion proteins. Am J Physiol 1998; 275:177-82.
22. Liu X, Carlisle DL, Swick MC, Gaither-Davis A, Grandis JR, Siegfried JM. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Exp Cell Res 2007; 313:1361-72.
23. Rozengurt E. Signal transduction pathways in the mitogenic response to G protein-coupled neuropeptide receptor agonists. J Cell Physiol 1998; 177:507-17. (Pubitemid 28541576)
24. Rodriguez-Fernandez JL, Rozengurt E. Bombesin, bradykinin, vasopressin and phorbol esters rapidly and transiently activate Src family tyrosine kinases in Swiss 3T3 cells. Dissociation from tyrosine phosphorylation of p125 focal adhesion kinase. J Biol Chem 1996; 271:27895-901.
25. Thomas SM, Grandis JR, Wentzel AL, Gooding WE, Lui VW, Siegfried JM. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia 2005; 7:426-31.
26. Lui VW, Thomas SM, Zhang Q, Wentzel AL, Siegfried JM, Li JY, et al. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 2003; 22:6183-93. (Pubitemid 37281648)
27. Xiao D, Qu X, Weber HC. Activation of extracellular signal-regulated kinase mediates bombesin-induced mitogenic responses in prostate cancer cells. Cell Signal 2003; 15:945-53. (Pubitemid 36859806)
28. Kip1 by diverse signalling pathways in Swiss 3T3 cells. Oncogene 1997; 14:1759-66.
29. Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol 2007; 18:1457-66.
30. Zhou J, Chen J, Mokotoff M, Ball ED. Targeting gastrin-releasing peptide receptors for cancer treatment. Anticancer Drugs 2004; 15:921-7.
31. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001; 22:248-91.
32. 2) receptor antagonist. Bioorg Med Chem Lett 1998; 8:2589-94.
33. 2 or its derivatives. Proc Natl Acad Sci USA 1994; 91:12664-8.
34. Halmos G, Schally AV. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095. Proc Natl Acad Sci USA 1997; 94:956-60.
35. Szepeshazi K, Schally AV, Halmos G, Lamharzi N, Groot K, Horvath JE. A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers. Proc Natl Acad Sci USA 1997; 94:10913-8. (Pubitemid 27430835)
36. Koppan M, Halmos G, Arencibia JM, Lamharzi N, Schally AV. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer 1998; 83:1335-43. (Pubitemid 28460084)
37. Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, et al. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate 2005; 64:303-15.
38. Kanashiro CA, Schally AV, Varga JL, Hammann B, Halmos G, Zarandi M. Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma. Cancer Lett 2005; 226:123-31.
39. Kanashiro CA, Schally AV, Nagy A, Halmos G. Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms. Int J Oncol 2005; 27:169-74.
40. Stangelberger A, Schally AV, Varga JL, Zarandi M, Cai RZ, Baker B, et al. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling. Eur J Cancer 2005; 41:2735-44.
41. Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proc Natl Acad Sci USA 2003; 100:15836-41.
42. Chatzistamou I, Schally AV, Sun B, Armatis P, Szepeshazi K. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c-jun and c-fos oncogene expression by bombesin antagonists. Br J Cancer 2000; 83:906-13.
43. Kiaris H, Schally AV, Sun B, Armatis P, Groot K. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin- releasing peptide. Oncogene 1999; 18:7168-73.
44. Hohla F, Schally AV, Kanashiro CA, Buchholz S, Baker B, Kannadka C, et al. Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2 and pAkt. Proc Natl Acad Sci USA 2007; 104:18671-6.
45. Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling. Int J Cancer 2004; 112:570-6.
46. Kanashiro CA, Schally AV, Cai RZ, Halmos G. Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma. Anticancer Drugs 2005; 16:159-65. (Pubitemid 40250611)
47. Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. Int J Oncol 2007; 30:1019-28.
48. Heuser M, Schlott T, Schally AV, Kahler E, Schliephake R, Laabs SO, et al. Expression of gastrin releasing Peptide receptor in renal cell carcinomas: a potential function for the regulation of neoangiogenesis and microvascular perfusion. J Urol 2005; 173:2154-9. (Pubitemid 40675272)
49. Schwartsmann G, DiLeone LP, Horowitz M, Schunemann D, Cancella A, Pereira AS, et al. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs 2006; 24:403-12.
50. Moody TW, Leyton J, Garcia-Marin L, Jensen RT. Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. Eur J Pharmacol 2003; 474:21-9. (Pubitemid 37289142)
51. Moody TW, Nakagawa T, Kang Y, Jakowlew S, Chan D, Jensen RT. Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation. J Mol Neurosci 2006; 28:231-8. (Pubitemid 43780315)
52. Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, et al. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther 2007; 6:1414-24. (Pubitemid 46712005)
53. Lango MN, Dyer KF, Lui VW, Gooding WE, Gubish C, Siegfried JM, et al. Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J Natl Cancer Inst 2002; 94:375-83. (Pubitemid 34257481)
54. Kelley MJ, Linnoila RI, Avis IL, Georgiadis MS, Cuttitta F, Mulshine JL, et al. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 1997; 112:256-61. (Pubitemid 27343628)
55. Guojun W, Wei G, Kedong O, Yi H, Yanfei X, Qingmei C, et al. A novel vaccine targeting gastrin-releasing peptide: efficient inhibition of breast cancer growth in vivo. Endocr Relat Cancer 2008; 15:149-59.
56. Langer DA, Kautzman D, Kane MA. Inhibition of proliferation of human small cell lung cancer cells expressing an autocrine system for gastrin releasing peptide by antisense oligodeoxynucleotides to gastrin releasing peptide receptor. Lung Cancer 2002; 36:235-42. (Pubitemid 34497120)
57. Zhou J, Chen J, Zhong R, Mokotoff M, Shultz LD, Ball ED. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes. Clin Cancer Res 2006; 12:2224-31.
58. Zhou J, Chen J, Mokotoff M, Zhong R, Shultz LD, Ball ED. Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer. Clin Cancer Res 2003; 9:4953-60.
59. Safavy A, Raisch KP, Khazaeli MB, Buchsbaum DJ, Bonner JA. Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. J Med Chem 1999; 42:4919-24.
60. Safavy A, Raisch KP, Mantena S, Sanford LL, Sham SW, Krishna NR, et al. Design and development of water-soluble curcumin conjugates as potential anticancer agents. J Med Chem 2007; 50:6284-8.
61. Moody TW, Mantey SA, Pradhan TK, Schumann M, Nakagawa T, Martinez A, et al. Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J Biol Chem 2004; 279:23580-9. (Pubitemid 38685672)
62. Nagy A, Armatis P, Cai RZ, Szepeshazi K, Halmos G, Schally AV. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci USA 1997; 94:652-6. (Pubitemid 27053688)
63. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004; 15:300-10. (Pubitemid 39193184)
64. Nagy A, Schally AV. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Curr Pharm Des 2005; 11:1167-80.
65. Engel JB, Schally AV, Dietl J, Rieger L, Honig A. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm 2007; 4:652-8. (Pubitemid 350004264)
66. Engel JB, Schally AV, Halmos G, Baker B, Nagy A, Keller G. Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins. Eur J Cancer 2005; 41:1824-30.
67. Engel JB, Schally AV, Halmos G, Baker B, Nagy A, Keller G. Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocr Relat Cancer 2005; 12:999-1009. (Pubitemid 41815792)
68. Buchholz S, Schally AV, Engel JB, Hohla F, Heinrich E, Koester F, et al. Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci USA 2007; 104:1943-6.
69. Zwanziger D, Beck-Sickinger AG. Radiometal targeted tumor diagnosis and therapy with peptide hormones. Curr Pharm Des 2008; 14:2385-400.
70. Smith CJ, Volkert WA, Hoffman TJ. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 2005; 32:733-40.
71. Ansquer C, Kraeber-Bodere F, Chatal JF. Current status and perspectives in peptide receptor radiation therapy. Curr Pharm Des 2009; 15:2453-62.
72. 18F-FDG. J Nucl Med 2007; 48:1245-50.
73. Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000; 27:1694-9.
74. Van de Wiele C, Phonteyne P, Pauwels P, Goethals I, Van den Broecke R, Cocquyt V, et al. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med 2008; 49:260-4.
75. 177Lu-AMBA. Eur J Nucl Med Mol Imaging 2007; 34:95-100.
76. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006; 47:1144-52.